Noxopharm Ltd. has released a press release.
SOF-SKN manufacturing begins to ensure clinical trial readi
Earlier from Noxopharm
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
- New data shows SOF-SKN active ingredient efficacy